From: Optimization of osteoporosis and osteopenia management among renal transplant recipients
Parameter (reference) | Denosumab (n = 52) | Ibandronate (n = 48) | P value |
---|---|---|---|
Gender (male/female) | 24/28 | 21/27 | 0.80a |
Age | 56.08 (± 14) | 53.32 (± 13) | 0.54a |
Osteopenia/ Osteoporosis patients | 40/12 | 37/11 | 0.98a |
Time after Transplant (months) | 24.9 (± 13.85) | 25.46 (± 14.18) | 0.84a |
Body Mass Index (kg/m2) | 29.9 (± 5.2) | 29.6 (± 4.6) | 0.71a |
Vitamin D (75–250 nmol/L) | 63.52 (± 8.1) | 55.07 (± 9.7) | 0.15a |
Calcium (2.2–2.5 mmol/L) | 2.33 (± 0.17) | 2.35 (± 14) | 0.19a |
Phosphorous (0.8–1.5 mmol/L) | 1.18 (± 0.15) | 1.17 (± 0.26) | 0.69a |
Serum creatinine (40–115 µmol/L) | 105.4 (± 29.45) | 109.6 (± 28.68) | 0.07a |
Urea (2.5–6.4 mmol/L) | 5.95 (± 2.5) | 5.35 (± 2.89) | 0.32a |
Sodium (135–145 mmol/L) | 138.25 (± 3.23) | 138.82 (± 4.07) | 0.77a |
Chloride (98–107 mmol/L) | 103.86 (± 2.95) | 103.2 (± 3.63) | 0.88a |
Uric acid (208–425 µmol/L) | 364.75 (± 79) | 372.69 (± 65) | 0.17a |
Total Cumulative Steroid (gm) | 1.58 (± 0.25) | 1.51 (± 0.30) | 0.48a |
T-score | |||
Spinal Osteoporosis | −3.13 (± 0.6) | −2.80 (± 0.3) | 0.26a |
Spinal Osteopenia | −1.9 (± 0.27) | −1.6 (± 0.15) | 0.44a |
Hip Osteoporosis | −3.45 (± 0.4) | −3.1 (± 0.6) | 0.94a |
Hip Osteopenia | −1.5 (± 0.2) | −1.4 (± 0.23) | 0.94a |
Immunosuppression | |||
Predinsolone | 52 (100%) | 48 (100%) | – |
Mycophenolate | 52 (100%) | 48 (100%) | – |
Tacrolimus | 42 (80%) | 36 (75%) | |
Cyclosporine | 10 (20%) | 12 (25%) | 0.49a |